ArticleTranslational oncology2021

Tumor-targeting anti-EGFR x anti-PD1 bispecific antibody inhibits EGFR-overexpressing tumor growth by combining EGFR blockade and immune activation with direct tumor cell killing.

Li Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.